Bayer Stock - Weekly review and sector comparison
21.06.2026 - 13:45:16 | ad-hoc-news.de
Edited by ad hoc news Background & Management Desk. Verified prior to publication on 06/21/2026, 13:44 CET. Details in the imprint.
Bayer (DE000BAY0017) remains a core name in the European healthcare and chemicals landscape. With no fresh ad-hoc release or major analyst action over the past 24 hours, this Sunday review looks at the past week in Bayer’s stock and its position relative to key sector peers.
All news and data on Bayer stock
Background reports, company disclosures and market data on Bayer are collected in the ad hoc news topic overview and on the company’s investor-relations pages.
How Bayer shares ended the week
Bayer shares most recently traded around EUR 37.80 on Xetra at the end of the week, based on exchange data for 06/20/2026. The stock moved in a narrow corridor over the past five trading days, reflecting a broadly subdued tone in European blue chips.
In this period, the quote oscillated roughly in the high EUR 37 range on low to moderate volumes, according to German market data services. That pattern mirrors a cautious stance across the Standard & Poor’s 500 index healthcare cohort, where large diversified names also showed only limited price swings.
Position in pharma and chemicals peer group
Within the DAX, Bayer sits alongside other healthcare-focused names such as Merck and Siemens Healthineers, as well as chemicals groups like BASF. Over the past week, Bayer’s muted move contrasted with somewhat more active trading in several peers that reacted to stock-specific news.
Sector-wide, investors continued to track themes such as drug pricing, R&D pipelines and exposure to crop-science markets. Large European pharma and chemical stocks overall traded sideways to slightly softer, weighed by macroeconomic uncertainty and selective profit-taking after earlier rebounds.
Litigation, restructuring and balance-sheet backdrop
Beyond the weekly tape, the medium-term narrative for Bayer is still dominated by litigation risks in the United States, restructuring measures and balance-sheet considerations. Management has previously flagged cost savings and portfolio streamlining to strengthen profitability and financial flexibility.
Against this backdrop, market participants regularly compare Bayer’s valuation to global peers facing their own legal, regulatory and pipeline challenges. While the stock currently trades well below levels seen several years ago, investors remain focused on execution of strategic initiatives and potential legal overhang resolution.
How analysts frame the consensus
Analyst consensus data compiled by financial portals indicate a mixed but broadly constructive stance on Bayer, with a spread of recommendations from Sell to Buy. Price targets cluster above the current quote, implying upside in many models, though dispersion is meaningful.
Several houses emphasize that progress on litigation and deleveraging are key triggers for any sustained re-rating. At the same time, they highlight the underlying strength of Bayer’s pharmaceutical and crop-science franchises, which provide recurring cash flows and a diversified earnings base.
Weekly review within the crop-science segment
On the crop-science side, the broader agricultural-inputs sector had a steady week, with farmers and distributors still digesting pricing and demand trends for seeds and crop-protection products. Global peers like Syngenta Group and Corteva also traded in relatively calm ranges.
Investors in this sub-sector are closely monitoring seasonal demand patterns in key regions such as North America and Europe. For Bayer, the crop-science business remains an important earnings pillar, and its performance is routinely benchmarked against both listed and privately held competitors.
Background on Bayer’s diversified business
Bayer’s business model combines pharmaceuticals, consumer health and crop-science operations under one corporate roof. The group develops and sells prescription medicines, over-the-counter products and agricultural inputs ranging from herbicides to high-yield seeds.
In recent years, this diversification has offered some cushioning against single-market shocks, but it has also made strategic decisions about portfolio focus and capital allocation more complex. Market observers therefore pay close attention to any management statements about potential divestments, spin-offs or structural changes.
The product behind the stock
One of Bayer’s best-known consumer health products is the Aspirin pain reliever, a brand with more than a century of market presence. The company also markets a broad range of prescription drugs and crop-protection products, but Aspirin remains emblematic of its global healthcare reach.
Where the stock trades today
The shares of Bayer (DE000BAY0017) trade on Xetra at EUR 37.80 as of 06/20/2026, 17:35 CET, according to German exchange data.
Key facts on Bayer stock
- Company: Bayer AG
- ISIN: DE000BAY0017
- WKN: BAY001
- Ticker: BAYN
- Venue: Xetra
- Price (as of 06/20/2026, 17:35 CET): 37.80 EUR
- Market cap: around 36,000,000,000 EUR (as of 06/20/2026, based on Xetra data and recent share count)
- Sector / Industry: Healthcare / Pharmaceuticals & Agricultural Chemicals
- Index membership: DAX, Euro Stoxx 50, Stoxx Europe 600
- Next earnings date: not officially scheduled
This article was AI-assisted and editorially reviewed. Price and company data without warranty; prices and dates may change at short notice. No investment advice, no buy or sell recommendation. Trading securities involves risk up to total loss of capital.
